This open-labeled randomized controlled clinical trial investigated the effects of daily flaxseed consumption on frailty, sarcopenia, inflammation, and disease severity in patients with liver cirrhosis. Over a 12-week intervention, patients receiving 30 g/day of flaxseed powder showed significant reductions in liver frailty index, sarcopenia risk (SARC-F), waist circumference, percent body fat, inflammatory marker hs-CRP, and MELD-Na disease severity score compared with baseline and control. Muscle strength, assessed by hand-grip, improved in the flaxseed group, while it declined in controls. The findings suggest that flaxseed may serve as a beneficial functional food to improve muscle strength, reduce frailty and sarcopenia, and alleviate inflammation and disease severity in individuals with liver cirrhosis.
Resource type:
Peer review